Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | MPL | P40238 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756206 | 0.86 | MMP2 (0.42) | MMP2CA2POLBALDH1A1TDP1 | |
| SCHEMBL396017 | 0.83 | CA2 (0.55) | MMP2CA2POLBALDH1A1TDP1 | |
| SCHEMBL30390082 | 0.83 | MMP2 (0.39) | MMP2CA2POLBALDH1A1TDP1 | |
| SCHEMBL6757407 | 0.83 | MMP2 (0.39) | MMP2CA2POLBALDH1A1TDP1 | |
| SCHEMBL689226 | 0.79 | MMP2 (0.37) | MMP2CA2ALDH1A1TDP1TSHR | |
| SCHEMBL19837804 | 0.78 | MMP2 (0.36) | MMP2CA2POLBTDP1L3MBTL1 | |
| SCHEMBL19326634 | 0.78 | MMP2 (0.36) | MMP2CA2TSHRALOX15 | |
| SCHEMBL564371 | 0.77 | CA2 (0.50) | MMP2CA2ALDH1A1TDP1TSHR | |
| SCHEMBL6282684 | 0.77 | CA2 (0.70) | MMP2CA2POLBALDH1A1TDP1 | |
| SCHEMBL16738114 | 0.77 | MMP2 (0.35) | MMP2CA2TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253006-B2 | Assay for the detection of the phenylpiperazine family | RANDOX LABORATORIES LIMITED (GB) | 2019-04-09 | — | — | US | claimed |
| US-20160229824-A1 | ASSAY FOR THE DETECTION OF THE PHENYLPIPERAZINE FAMILY | NORTHERN BANK LIMITED (IE) | 2016-08-11 | — | — | US | claimed |
| EP-4619388-A1 | CATHEPSIN L INHIBITORS | Biofront Therapeutics (Beijing) Co., Ltd. (CN) | 2025-09-24 | — | — | EP | disclosed |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-119775261-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119212781-A | Method for preparing m-hydroxy benzotrifluoride (MHBTF) | 迪帕克亚硝酸盐有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119212781-A | Method for preparing m-hydroxy benzotrifluoride (MHBTF) | 迪帕克亚硝酸盐有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-115427404-B | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240409533-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2024-12-12 | — | — | US | disclosed |
| CN-113874074-B | HMOX1 inducers | 米托布里奇公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12071433-B2 | HMOX1 inducers | Astellas Engineered Small Molecules US, Incorporated (US) | 2024-08-27 | — | — | US | disclosed |
| US-5886044-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0896531-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-17 | — | — | EP | disclosed |
| US-5780483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997049286-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0809492-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997029743-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996025157-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-22 | — | — | WO | disclosed |
| US-4263441-A | BENZOXAZOLE DERIVATIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-04-21 | — | — | US | disclosed |
| EP-0002030-A1 | Fluorinated benzazole derivatives, method for their preparation and their use as optical brighteners | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | MMP2 4502/4885CA2 4707/4885POLB 238/4885 |
| US-20240409533-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, HMBS | MMP2 1059/4885CA2 2497/4885POLB 3184/4885 |
| US-12071433-B2 | HMOX1 inducers | HMOX1, HMOX2, HMBS | MMP2 994/4885CA2 2228/4885POLB 2840/4885 |
| US-10253006-B2 | Assay for the detection of the phenylpiperazine family | METAP2, DCPS, NPEPPS | MMP2 1087/4885CA2 3647/4885POLB 2782/4885 |
| US-20160229824-A1 | ASSAY FOR THE DETECTION OF THE PHENYLPIPERAZINE FAMILY | METAP2, DCPS, NPEPPS | MMP2 1087/4885CA2 3647/4885POLB 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.